Coherus BioSciences (CHRS) said Tuesday it agreed to repurchase about $170 million of 1.5% convertible senior subordinated notes due 2026 in privately negotiated deals.
The company said that after completion of the repurchases, about $60 million principal amount of convertible notes will remain outstanding.
The repurchases are conditional on the closing of the UDENYCA franchise divestiture to Intas Pharmaceuticals, the company said.
After completing the divestiture, Coherus plans to repurchase the remaining convertible notes.
Shares of the company were up 1.7% in recent trading.
Price: 0.82, Change: +0.01, Percent Change: +1.73
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。